Saltar al contenido
Immunomodulation Lab
Immunomodulation LabImmunomodulation Lab
  • HOME
  • RESEARCH
  • TEAM
  • PUBLICATIONS
  • FUNDING
  • NEWS
  • CONTACT
Linkedin page opens in new windowX page opens in new window
  • HOME
  • RESEARCH
  • TEAM
  • PUBLICATIONS
  • FUNDING
  • NEWS
  • CONTACT

Archivos de etiqueta: news

Pfizer Foundation awards the Immunomodulation Lab

Pfizer Foundation awards the Immunomodulation Lab

NewsPor Carlos del Fresnonoviembre 11, 2024Deja un comentario

Pfizer Foundation awards our laboratory with the “Premio Fundación Pfizer – ITEMAS al mejor proyecto de innovación en salud surgido de las Unidades y Unidades Asociadas de la Plataforma ITEMAS-ISCIII”. This award recognized the value of our project regarding the use of blood liquid biopsy to identify patients suffering from colon polyps or tumors. Beyond…

Demo-Day-APTEnisa-Start-2024

Demo Day closes APTEnisa Start 2024 brilliantly

NewsPor Carlos del Fresnoseptiembre 6, 2024Deja un comentario

Continuing with our efforts to bring the results generated in the lab to our patients, and in line with our previous achievement granted by ASEICA-La Caixa, we have been selected by Fundación Parque Científico de Madrid as part of the program APTEnisa Start 2024. We continue pushing our project focused on a blood-based liquid biopsy…

Selected by ASEICA – La Caixa

NewsPor Carlos del Fresnojulio 2, 2024Deja un comentario

Selected by ASEICA – La Caixa   In our lab, as part of the research line where we are looking for cancer biomarkers, we are developing a project for the establishment of a blood-based liquid biopsy to identify patients suffering from colon polyps or tumors. As a translational laboratory, we aim to bring our research…

Immunomodulation Lab

Copyright 2025 Artbits All rights reserved. Cookies policy · Privacy policy · Legal Warning

  • Research
  • Publications
  • Contact
Useful Links
Ir a Tienda
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site, we'll assume you're ok with it.AcceptNoPrivacy Policy